According to TipRanks, Risinger is a 2-star analyst with an average return of 2.5% and a 55.56% success rate. Risinger covers the Healthcare sector, focusing on stocks such as Pfizer, Sanofi, and Eli Lilly & Co.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Halozyme with a $54.60 average price target, representing a 25.78% upside. In a report released on August 10, JMP Securities also reiterated a Buy rating on the stock with a $60.00 price target.
Based on Halozyme’s latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $152.37 million and a net profit of $22.69 million. In comparison, last year the company earned a revenue of $136.46 million and had a net profit of $91.46 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Halozyme Therapeutics, Inc. is a biopharmaceutical company, which engages in research, development & commercialization of human enzymes and drug candidates. It focuses on novel oncology therapies that target the tumor microenvironment. Its products include PEGPH20, HTI-1511, PEG-ADA2, and HYLENEX recombinant. The company was founded by Gregory Ian Frost on February 26, 1998 and is headquartered in San Diego, CA.
Read More on HALO:
- SVB Securities Remains a Buy on Guardant Health (GH)
- SVB Securities Sticks to Their Buy Rating for Prometheus Biosciences (RXDX)
- SVB Securities Keeps Their Hold Rating on Talaris Therapeutics (TALS)
- PG&E (PCG) Receives a Buy from Mizuho Securities
- Robert W. Baird Sticks to Their Buy Rating for Navitas Semiconductor (NVTS)